• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Anti-Obesity Medications
    3 Drugs classified under this therapeutic system


    All the Therapeutic System Drugs

    Razin
    CTS
    RX
    not in the basket chart
    Razin

    CNS Stimulant. Phentermine (as resinate) 15 mg.
    CAPS (Sustained Action): 30. 1 cap. aft.
    breakf. accord. to instruct.
    Manage. exog. obesity, short term adjust. in
    regimen of wt. reduct. based on calorie
    restrict.

    Saxenda
    Novo Nordisk
    RX
    not in the basket chart
    Saxenda

    Human Glucagon-Like Peptide-1. Liraglutide 6 mg/ml.
    PRE-FILL. PENS: 5. Init. 0.6 mg dly. The dose should be incr. to 3.0 mg dly. in increm. of 0.6 mg with at least one week  interv. to improve GI tolerabil. If escal.  to the next dose step is not tolerated for two consec. wks., consider discount. tmt. Dly. doses higher than 3.0 mg are not recomm.
    As an  adjun. a reduced-calorie diet and incr. phys. active. for weight manag. in adult pts. with an init. BMI of  ≥ 30 kg/m² (obese), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid. such as dysglycaemia (pre-diab. or type 2 diab. mell.), hypertens. or dyslipidaemia, and who have failed a prev. weight manag. intervent. Tmt. should be discount. after 12 wks. on the 3.0 mg/day dose if pts. have not lost at least 5% of their init. bdy. wt.
    C/I: Hyperses.

    Xenical
    Tzamal
    RX
    not in the basket chart
    Xenical

    Lipase Inhibitor. Orlistat 120 mg.
    CAPS: 7, 21, 42, 84 x 120 mg.
    Adults and child over 12 yrs:
    1 cap. 3 x dly.
    In conjunct. with mildly hypocaloric diet
    for obese patients with a BMI greater or
    equal to 30 kg/m2, or overweight patients
    (BMI >28 kg/m2) with assoc. risk factors.
    C/I: Hypersens., chron. malabsorpt.
    syndr., cholestasis, lact.


    Other therapeutic systems under Affecting Nutrition and Metabolism

    CLOSE